ArticleThe Lancet. Rheumatology2022
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry.
Open access · bronzeAbstract read
In one paragraph
Article in The Lancet. Rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- JAK inhibitors and COVID-19.Journal for immunotherapy of cancer · 2022Pooled it
- SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.Frontiers in immunology · 2022Trial
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement.The Australasian journal of dermatology · 2025Article
- Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitors.BMC rheumatology · 2025Article
- Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.Infectious diseases and therapy · 2025Review
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety.Dermatology practical & conceptual · 2024Article
- Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases.Vaccines · 2024Review
- COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases.Vaccines · 2023Review
- Considerations for Pharmacologic Management of Rheumatoid Arthritis in the COVID-19 Era: a Narrative Review.Current rheumatology reports · 2023Review
- Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination.Clinical rheumatology · 2023Article
- Article
- JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in anFrontiers in immunology · 2023Article
- Pharmacological therapies and drug development targeting SARS-CoV-2 infection.Cytokine & growth factor reviews · 2022Review
- Article
- Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.RMD open · 2022Article
- Article
- Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.Vaccine · 2022Review
- A Comprehensive Overview of Globally Approved JAK Inhibitors.Pharmaceutics · 2022Review
- The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study.Biomedicines · 2022Article
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 16 institutions in 1 country.
Raphaèle SerorDepartment of Rheumatology, Université Paris-Saclay, INSERM U1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, 94275 Le Kremlin Bicêtre, Paris, France.
Marine CamusDepartment of Rheumatology, Université Paris-Saclay, INSERM U1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, 94275 Le Kremlin Bicêtre, Paris, France.
Jean-Hugues SalmonUniversity of Reims Champagne-Ardenne, Faculty of Medicine, EA 3797, Rheumatology Department, Maison Blanche Hospital, Reims University Hospitals, Reims, France.
Christian RouxDepartment of Rheumatology, LAMHESS, IBV CNRS IMR 7277 INSERM U1091 UNS, University Cote d'Azur, CHU du Nice, Nice, France.
Emmanuelle DernisDepartment of Rheumatology, CH du Mans, Le Mans, France.
André BaschDepartment of Rheumatology, Infirmerie Protestante de Lyon, Caluire-et-Cuire, France.
Vincent GermainDepartment of Rheumatology, CH de Pau, Pau, France.
Charles LeskeDepartment of Rheumatology, CH de Cholet, Cholet, France.
Steeve BrousseauDepartment of Rheumatology, Université Bordeaux, CHU Bordeaux, Bordeaux, France.
Marie-Elise TruchetetDepartment of Rheumatology, Université Bordeaux, CHU Bordeaux, Bordeaux, France.
André RamonDepartment of Rheumatology, CHU Dijon, Dijon, France.
Jacques-Eric GottenbergDepartment of Rheumatology, CHU de Strasbourg, Centre National de Référence pour les Maladies Auto-Immunes Systémiques Rares, IBMC, CNRS, UPR3572, Université de Strasbourg, Strasbourg, France.
Renaud FeltenDepartment of Rheumatology, CHU de Strasbourg, Centre National de Référence pour les Maladies Auto-Immunes Systémiques Rares, IBMC, CNRS, UPR3572, Université de Strasbourg, Strasbourg, France.
Fabienne CouryDepartment of Rheumatology, Lyon University Hospital and University of Lyon 1, Lyon, France.
Antoine ColombeyDepartment of Rheumatology, CH de Saint-Nazaire, Saint-Nazaire, France.
Clément PratiDepartment of Rheumatology, CHU du Besancon, Besancon, France.
Xavier MarietteDepartment of Rheumatology, Université Paris-Saclay, INSERM U1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, 94275 Le Kremlin Bicêtre, Paris, France.
JérÔme AvouacDepartment of Rheumatology, Hôpital Cochin, AP-HP.CUP, Université de Paris, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRUniversité de Bordeaux · FRCentre Hospitalier de Lens · FRCentre Hospitalier De Pau · FRCentre Hospitalier du Mans · FRCentre Hospitalier Saint-Nazaire · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Reims · FRCentre Hospitalier Universitaire Dijon Bourgogne · FRCentre National de la Recherche Scientifique · FRHôpital Cochin · FRInfirmerie Protestante · FRInserm · FRLaboratoire Motricité Humaine Éducation Sport Santé · FRUniversité Claude Bernard Lyon 1 · FRUniversité de Strasbourg · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.